Clinical Performance of Nano Plus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease

December 29, 2016 updated by: Tao Ling, Xijing Hospital

Safety and Efficacy of Polymer-free Sirolimus-eluting Coronary Stents in Patients With Coronary Artery Disease.

The study aims to evaluate the safety and efficacy of polymer-free sirolimus-eluting coronary stent system (NANO plus) in patients with coronary artery disease . The primary endpoint is target lesion failure, a composite endpoint of cardiac death, target vessel related myocardial infarction and clinically-driven target lesion revascularization at 1 year follow-up.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, multicenter, single arm clinical registry investigating the safety and efficacy of polymer-free sirolimus-eluting coronary stent system (NANO plus) in patients with coronary artery disease . In total, we plan to recruit 2500 patients in real world setting. The patients will be followed clinically at 1-, 6- month and 1-, 2-, 3-, 4-, 5-year. All clinical data will be collected and managed by statistical center, clinical endpoint adjudication committee.

Study Type

Observational

Enrollment (Anticipated)

2500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Chen Wang, PhD
  • Phone Number: 15802929290

Study Contact Backup

  • Name: Jin-Zan Cai, MSc
  • Phone Number: 15720800327

Study Locations

    • Shanxi
      • Xi'an, Shanxi, China
        • Recruiting
        • Xijing Hospital
        • Contact:
          • Chen Wang
          • Phone Number: 15802929290

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with coronary artery disease

Description

Inclusion Criteria:

  • 18-85 years old, male or non-pregnancy female;
  • Patients with coronary artery disease who match the indication of stent implantation;
  • Patients who can understand the nature of the study, agree to participate and accept clinical follow-up;

Exclusion Criteria:

  • Patients who can not tolerate the material or medication in this study;
  • Pregnancy or lactation women
  • Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;
  • Patients are, in the opinion of the investigator, unable to comply with the requirements of the study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
NANO Plus SES
All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
target lesion failure (TLF)
Time Frame: 12 months
cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Target lesion failure
Time Frame: 1、6、12、24、36、48、60 months
a composite endpoint of cardiac death, target lesion related myocardial infarction, and/or target lesion revascularization
1、6、12、24、36、48、60 months
Patient oriented composite endpoint
Time Frame: 1、6、12、24、36、48、60 months
a composite endpoint of all cause death, all myocardial infarction and all revascularization
1、6、12、24、36、48、60 months
all cause death
Time Frame: 1、6、12、24、36、48、60 months
1、6、12、24、36、48、60 months
cardiac death
Time Frame: 1、6、12、24、36、48、60 months
1、6、12、24、36、48、60 months
Myocardial infarction
Time Frame: 1、6、12、24、36、48、60 months
1、6、12、24、36、48、60 months
Stent thrombosis
Time Frame: 1、6、12、24、36、48、60 months
1、6、12、24、36、48、60 months
Target lesion revascularization
Time Frame: 1、6、12、24、36、48、60 months
1、6、12、24、36、48、60 months
Target vessel revascularization
Time Frame: 1、6、12、24、36、48、60 months
1、6、12、24、36、48、60 months
target lesion failure
Time Frame: 1、6、24、36、48、60 months
cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization
1、6、24、36、48、60 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Yao-Jun Zhang, PhD, Nanjing First Hospital, Nanjing Medical University
  • Principal Investigator: Lin Tao, PhD, Xijing Hospital
  • Principal Investigator: Yue Li, PhD, The First Clinical Hospital affiliated to Harbin Medical University
  • Principal Investigator: Zhiqi Sun, PhD, Daqing oilfield central hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2016

Primary Completion (Anticipated)

January 1, 2018

Study Completion (Anticipated)

January 1, 2022

Study Registration Dates

First Submitted

October 6, 2016

First Submitted That Met QC Criteria

October 6, 2016

First Posted (Estimate)

October 10, 2016

Study Record Updates

Last Update Posted (Estimate)

December 30, 2016

Last Update Submitted That Met QC Criteria

December 29, 2016

Last Verified

December 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • NANOxijing001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.